GE Healthcare aims to end unpredictability in early drug research
This article was originally published in Scrip
Better consistency of the cells used in early-stage drug research could save R&D departments millions of dollars and a lot of wasted time and effort. At GE Healthcare, the commercialisation of reliable stem cell lines is just around the corner, head of cell technologies R&D Dr Stephen Minger tells Ashley Yeo.
You may also be interested in...
To the watching world, China dealt quickly and firmly with COVID-19. Seen from within, the health care system is still adapting to the pandemic, but the government is taking the longer view.
While personal data security must be balanced againt the right to health, winning “trust” is the key to taking AI adoption to the next stage, says a new report focused on the European market.
The latest guidance from the UK devices regulator fills in some of the information gaps for companies addressing the Northern Ireland and EU27 markets after this year, seen through the lens of Brexit.